Li Zhao,1 Yuanyuan Ren,1 Donghui Qin,2 Xue Yang,1 Zhuo Chen,1 Na Zhang1 

1Department of Cardiology, The Third Affiliated Hospital of Qiqihar Medical College, Qiqihar, 161000, People’s Republic of China; 2General Hospital, Qiqihar City Second Hospital, Qiqihar, People’s Republic of China

Correspondence: Na Zhang, Email 13904523506@163.com

Objective: To retrospectively compare the efficacy of Sacubitril/Valsartan and Benazepril in the treatment of heart failure in patients following acute myocardial infarction.
Methods: A retrospective analysis of clinical data was conducted for 103 patients with heart failure following acute myocardial infarction admitted to our hospital from January 2021 to January 2024. All patients met complete inclusion and exclusion criteria. Based on the treatment interventions received, they were divided into a control group (n=51) and an observation group (n=52). All patients received percutaneous coronary intervention (PCI) and conventional drug treatment upon admission. The control group received additional treatment with benazepril, while the observation group received Sacubitril/Valsartan on top of the baseline treatment. A comparison was made between the two groups in terms of clinical treatment outcomes, cardiac function indicators [left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDD), left ventricular ejection fraction (LVEF)], levels of inflammatory markers [high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6)], N-terminal pro-B-type natriuretic peptide (NT-proBNP), incidence of adverse reactions, major adverse cardiac events (MACEs), and 6-minute walking distance (6MWD).
Results: No patients were lost to follow-up. After six months of treatment, the observation group demonstrated significantly greater improvements in left ventricular function parameters (LVESV, LVEDD, and LVEF) and reductions in inflammatory markers (hs-CRP, IL-6) and NT-proBNP levels compared to the control group (P < 0.05). The observation group also had a significantly lower incidence of major adverse cardiac events (MACEs) (11.54% vs 31.37%, P < 0.05) and a greater improvement in 6-minute walking distance (P < 0.05). The incidence of adverse reactions was comparable between the two groups (P > 0.05).
Conclusion: Sacubitril/Valsartan is a safe and effective treatment for heart failure post-AMI, offering significant improvements in cardiac function, inflammatory response, exercise capacity, and a reduction in MACE risk.

Keywords: sacubitril/valsartan, heart failure following acute myocardial infarction, efficacy, cardiac function